share_log

UBS Downgrades Singular Genomics Sys to Neutral, Lowers Price Target to $4.5

Benzinga Real-time News ·  Aug 17, 2022 06:20

UBS analyst John Sourbeer downgrades Singular Genomics Sys (NASDAQ:OMIC) from Buy to Neutral and lowers the price target from $10 to $4.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment